BioCentury | Nov 1, 2019
Financial News

Nov. 1 Financial Quick Takes: Kira raises $13.8M series A; plus SinoMab, Tot, Shasqi and Sense Biodetection

...immunological disease company proposed to sell 182 million shares at HK$7.60-HK$9.60. Underwriters are CICC, Orient, China Everbright...
...in a IPO underwritten by ICBC International, Yuanta, China Renaissance, Head & Shoulders Financial Group, China Everbright...
BioCentury | Oct 26, 2018
Financial News

First close for China Everbright’s new healthcare fund

...$115.4 million). The CEL Healthcare Fund III's target is RMB1.5 billion ($216.3 million). According to China Everbright...
...total healthcare funds under management, with total funds under management exceeding HK$140 billion ($17.9 billion). China Everbright's...
...SZSE:300558). On Oct. 23, China Everbright was off HK$0.24 to HK$13.24. China Everbright Ltd. (HKSE:165), Hong Kong, China Chris Lieu China Everbright Ltd....
BioCentury | Oct 23, 2018
Financial News

First close for China Everbright’s new healthcare fund

...million). The CEL Healthcare Fund III's target size is RMB1.5 billion ($216.3 million). According to China Everbright...
...total healthcare funds under management, with total funds under management exceeding HK$140 billion ($17.9 billion). China Everbright's...
...Chinese biotech Betta Pharmaceuticals Co. Ltd. (SZSE:300558). On Tuesday, China Everbright was off HK$0.24 to HK$13.24. Chris Lieu China Everbright Ltd....
BioCentury | Jan 5, 2018
Company News

Ambrx gets Chinese rights to Tracon's carotuximab

...Pharmaceuticals Inc. (NASDAQ:TCON), San Diego, Calif. Ambrx Inc., La Jolla, Calif. Business: Cancer Allison Johnson carotuximab IV TRC105 Ambrx Inc. China Everbright Ltd. Hopu...
BioCentury | Jan 6, 2017
Company News

Ambrx, MabSpace deal

...under a 2011 deal. In 2015, Ambrx was acquired by a Chinese consortium, which included China Everbright Ltd....
BioCentury | Aug 8, 2016
Financial News

Ambrx completes venture financing

...Sinopharm Capital; Humanwell Healthcare; Shanghai Fosun Pharmaceutical Co. Ltd.; Hopu Investment Management Co. Ltd. ; China Everbright Ltd. WIR...
BioCentury | Aug 4, 2016
Financial News

Ambrx raises $45M

...Fund. Sinopharm Capital, Humanwell Healthcare Fund, Fosun Capital, Hopu Investments and the healthcare fund of China Everbright Ltd....
BioCentury | Mar 10, 2016
Targets & Mechanisms

Brown fat heats up

...was acquired by a consortium containing Shanghai Fosun Pharmaceutical Group Co. Ltd. , HOPU Investments, China Everbright Ltd....
BioCentury | Oct 19, 2015
Regulation

Unleashing China's innovators

...drug conjugates and long-acting proteins. The consortium included WuXi PharmaTech Inc. , HOPU Investments and China Everbright...
...lists. Companies and Institutions Mentioned Beijing Institute of Toxicology, Beijing, China ChinaBio LLC, Shanghai, China China Everbright Ltd....
BioCentury | May 25, 2015
Company News

Ambrx, China Everbright, Hopu Investment Management, Shanghai Fosun Pharmaceutical, WuXi PharmaTech deal

...under a 2011 deal (see BioCentury, Sept. 22, 2011). Ambrx Inc. , La Jolla, Calif. China Everbright Ltd....
Items per page:
1 - 10 of 12
BioCentury | Nov 1, 2019
Financial News

Nov. 1 Financial Quick Takes: Kira raises $13.8M series A; plus SinoMab, Tot, Shasqi and Sense Biodetection

...immunological disease company proposed to sell 182 million shares at HK$7.60-HK$9.60. Underwriters are CICC, Orient, China Everbright...
...in a IPO underwritten by ICBC International, Yuanta, China Renaissance, Head & Shoulders Financial Group, China Everbright...
BioCentury | Oct 26, 2018
Financial News

First close for China Everbright’s new healthcare fund

...$115.4 million). The CEL Healthcare Fund III's target is RMB1.5 billion ($216.3 million). According to China Everbright...
...total healthcare funds under management, with total funds under management exceeding HK$140 billion ($17.9 billion). China Everbright's...
...SZSE:300558). On Oct. 23, China Everbright was off HK$0.24 to HK$13.24. China Everbright Ltd. (HKSE:165), Hong Kong, China Chris Lieu China Everbright Ltd....
BioCentury | Oct 23, 2018
Financial News

First close for China Everbright’s new healthcare fund

...million). The CEL Healthcare Fund III's target size is RMB1.5 billion ($216.3 million). According to China Everbright...
...total healthcare funds under management, with total funds under management exceeding HK$140 billion ($17.9 billion). China Everbright's...
...Chinese biotech Betta Pharmaceuticals Co. Ltd. (SZSE:300558). On Tuesday, China Everbright was off HK$0.24 to HK$13.24. Chris Lieu China Everbright Ltd....
BioCentury | Jan 5, 2018
Company News

Ambrx gets Chinese rights to Tracon's carotuximab

...Pharmaceuticals Inc. (NASDAQ:TCON), San Diego, Calif. Ambrx Inc., La Jolla, Calif. Business: Cancer Allison Johnson carotuximab IV TRC105 Ambrx Inc. China Everbright Ltd. Hopu...
BioCentury | Jan 6, 2017
Company News

Ambrx, MabSpace deal

...under a 2011 deal. In 2015, Ambrx was acquired by a Chinese consortium, which included China Everbright Ltd....
BioCentury | Aug 8, 2016
Financial News

Ambrx completes venture financing

...Sinopharm Capital; Humanwell Healthcare; Shanghai Fosun Pharmaceutical Co. Ltd.; Hopu Investment Management Co. Ltd. ; China Everbright Ltd. WIR...
BioCentury | Aug 4, 2016
Financial News

Ambrx raises $45M

...Fund. Sinopharm Capital, Humanwell Healthcare Fund, Fosun Capital, Hopu Investments and the healthcare fund of China Everbright Ltd....
BioCentury | Mar 10, 2016
Targets & Mechanisms

Brown fat heats up

...was acquired by a consortium containing Shanghai Fosun Pharmaceutical Group Co. Ltd. , HOPU Investments, China Everbright Ltd....
BioCentury | Oct 19, 2015
Regulation

Unleashing China's innovators

...drug conjugates and long-acting proteins. The consortium included WuXi PharmaTech Inc. , HOPU Investments and China Everbright...
...lists. Companies and Institutions Mentioned Beijing Institute of Toxicology, Beijing, China ChinaBio LLC, Shanghai, China China Everbright Ltd....
BioCentury | May 25, 2015
Company News

Ambrx, China Everbright, Hopu Investment Management, Shanghai Fosun Pharmaceutical, WuXi PharmaTech deal

...under a 2011 deal (see BioCentury, Sept. 22, 2011). Ambrx Inc. , La Jolla, Calif. China Everbright Ltd....
Items per page:
1 - 10 of 12